ID

12657

Beskrivning

MIPSO Vergleichende Untersuchung der bakteriellen Mikrobiota in der Haut sowie dem Darm von Psoriasis-Patienten vor und nach systemischer Behandlung mit Adalimumab bzw. Ustekinumab oder Ciclosporin (EudraCT 2014-003022-40) Principal Investigator: Prof. Dr. Dr. h.c. Thomas A. Luger

Nyckelord

Versioner (4)
  1. 2015-11-17 2015-11-17 -
  2. 2015-12-08 2015-12-08 -
  3. 2015-12-08 2015-12-08 -
  4. 2016-07-23 2016-07-23 -
Uppladdad den

8 december 2015

DOI

För en begäran logga in.

Licens

Creative Commons BY-NC 3.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Determination Psoriasis MIPSO EudraCT 2014-003022-40

Tysk Engelsk

Eligibility Determination Psoriasis MIPSO EudraCT 2014-003022-40

1 Formulär  
Patient identification
Beskrivning

Patient identification

Patient number
Beskrivning

Patient Number

Datatyp

text

Date of consent
Beskrivning

Date of consent

Datatyp

date

Måttenheter
  • dd/mm/yyyy
dd/mm/yyyy
Date of screening
Beskrivning

Date of screening

Datatyp

date

Måttenheter
  • dd/mm/yyyy
dd/mm/yyyy
Inclusion criteria
Beskrivning

Inclusion criteria

Patients with at least moderate psoriasis vulgaris (PASI ≥ 10) plaque-type
Beskrivning

Patients with at least moderate psoriasis vulgaris (PASI ≥ 10) plaque-type.

Datatyp

boolean

≥18 years (male and female)
Beskrivning

≥18 years (male and female)

Datatyp

boolean

Indications for treatment with adalimumab, ustekinumab or cyclosporine in accordance with the guidelines for psoriasis and the individual prescribing information
Beskrivning

Indications for treatment with adalimumab, ustekinumab or cyclosporine in accordance with the guidelines for psoriasis and the individual prescribing information.

Datatyp

boolean

Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Beskrivning

Patients with moderate to severe chronic plaque psoriasis who have not responded to other systemic therapy including cyclosporine, methotrexate or PUVA or who have a contraindication or intolerance to such therapy exists.

Datatyp

integer

Additional inclusion criterion for patients who should receive ciclosporin
Beskrivning

Patients with at least moderate psoriasis vulgaris (PASI ≥ 10) plaque-type, which are not sufficiently treated with conventional systemic therapy.

Datatyp

integer

Exclusion criteria
Beskrivning

Exclusion criteria

Therapy with systemic immunosuppressants
Beskrivning

Therapy with systemic immunosuppressants (such as cyclosporine or methotrexate), adalimumab, etanercept, infliximab, or ustekinumab in a period of 5 half-lives of the respective medication before taking the initial swab specimens / biopsies.

Datatyp

boolean

Concurrent therapy with systemic immunosuppressants
Beskrivning

Concurrent therapy with systemic immunosuppressants.

Datatyp

boolean

Antibiotic therapy over a period of at least 4 weeks or during the study
Beskrivning

Antibiotic therapy over a period of at least 4 weeks before taking the initial swab specimens / biopsies or antibiotic therapy during the study.

Datatyp

boolean

Psoriasis patients who currently receive or have received phototherapy
Beskrivning

Psoriasis patients who currently receive or have received phototherapy for a period of 2 weeks before the withdrawal of the initial swab specimens / biopsies.

Datatyp

boolean

Patients who can not interrupt the local, topical therapy with calcineurin inhibitors or vitamin D3 analogues in the skin areas
Beskrivning

Patients who can not interrupt the local, topical therapy with calcineurin inhibitors or vitamin D3 analogues in the conditions laid down for the smear preparations / biopsies skin areas. The topical treatment with calcineurin inhibitors or vitamin D3 analogs can be continued in lesional skin areas that are not intended for smear preparations / biopsies. In the conditions laid down for the smear preparations / biopsies skin areas must be done 7 days prior to taking the samples no topical therapy.

Datatyp

boolean

Clinically significant active infection
Beskrivning

Clinically significant active infection (eg active tuberculosis or other severe infections such as sepsis and opportunistic infections). Latent tuberculosis. A history of latent or active tuberculosis that has not been adequately treated safely.

Datatyp

boolean

Chronic carriers of the hepatitis B virus (HBsAg positive)
Beskrivning

Chronic carriers of the hepatitis B virus (HBsAg positive).

Datatyp

boolean

HIV-positive patients
Beskrivning

HIV-positive patients.

Datatyp

boolean

Malignancies current or history
Beskrivning

Malignancies current or history.

Datatyp

boolean

Immunodeficient patients (primary disease or as a result of therapy)
Beskrivning

Immunodeficient patients (primary disease or as a result of therapy).

Datatyp

boolean

Patients receiving chemotherapy or radiation therapy
Beskrivning

Patients receiving chemotherapy or radiation therapy or currently one who received chemotherapy / radiotherapy within the last 12 months before the withdrawal of the initial swab specimens / biopsies.

Datatyp

boolean

Patients are not stable with uncontrolled chronic diseases
Beskrivning

Patients are not stable with uncontrolled chronic diseases that require continuous treatment (such as diabetes, hepatitis, organ transplantation), and from the perspective of the investigator.

Datatyp

boolean

Patients with other chronic skin diseases
Beskrivning

Patients with other chronic skin diseases such as atopic dermatitis or lupus erythematosus that may affect the cutaneous microbiota.

Datatyp

boolean

Patients with psychiatric comorbidity
Beskrivning

Patients with psychiatric comorbidity, which cause a lack or lack of capacity to consent.

Datatyp

boolean

Participation in another interventional examination
Beskrivning

Participation in another interventional examination before study completion in a period of 4 weeks and 5 half-lives of the former investigational, whichever is longer.

Datatyp

boolean

Pregnancy or lactation
Beskrivning

For childbearing women or men with female partners of childbearing unwillingness reliable forms of contraception (Pearl index <1) apply. With Stelara® patients treated these contraceptive methods have to at least 15 weeks after the end of treatment with Humira® patients treated for at least 5 months after the end of treatment continue.

Datatyp

boolean

Patients who were positive for MRSA
Beskrivning

Patients who were positive for MRSA in the history over a period of 6 months prior to withdrawal of the first swab specimens / biopsies.

Datatyp

boolean

Patients with psoriasis vulgaris exclusively in the head area
Beskrivning

Patients with psoriasis vulgaris exclusively in the head area.

Datatyp

boolean

Additional exclusion criteria Adalimumab
Beskrivning

Additional exclusion criteria Adalimumab

Hypersensitivity
Beskrivning

Hypersensitivity to the active substance or to any of the excipients of Humira®.

Datatyp

integer

Moderate to severe heart failure (NYHA class III / IV).
Beskrivning

Moderate to severe heart failure (NYHA class III / IV).

Datatyp

integer

Demyelinating diseases of the CNS
Beskrivning

Pre-existing or incipient demyelinating diseases of the CNS or peripheral nervous system.

Datatyp

integer

Concurrent therapy with Anakinra or Abatacept
Beskrivning

Concurrent therapy with anakinra or abatacept.

Datatyp

integer

Concomitant vaccination with live vaccines
Beskrivning

Concomitant vaccination with live vaccines. This applies for a period up to 5 months after end of therapy.

Datatyp

integer

Additional exclusion criteria Ustekinumab
Beskrivning

Additional exclusion criteria Ustekinumab

Hypersensitivity
Beskrivning

Hypersensitivity to the active substance or to any of the excipients of Stelara®, allergy to latex.

Datatyp

integer

Simultaneous vaccination with live viruses or live bacteria
Beskrivning

Simultaneous vaccination with live viruses or live bacteria. This applies for a period of 2 weeks prior to initiation of therapy with Stelara® until at least 15 weeks after end of therapy.

Datatyp

integer

Additional exclusion criteria Ciclosporin
Beskrivning

Additional exclusion criteria Ciclosporin

Hypersensitivity
Beskrivning

Known hypersensitivity to ciclosporin and / or against any of the excipients of the ciclosporin preparation.

Datatyp

integer

Uncontrolled arterial hypertension
Beskrivning

Uncontrolled arterial hypertension.

Datatyp

integer

Uncontrolled infectious diseases
Beskrivning

Uncontrolled infectious diseases.

Datatyp

integer

Not healed infection with varicella
Beskrivning

Not healed infection with varicella, incl. Herpes zoster infection, herpes simplex infections, and other viral infections (eg, mollusks, condyloma, multiple warts)

Datatyp

integer

Relevant renal impairment
Beskrivning

Relevant renal impairment

Datatyp

integer

Severe liver disease
Beskrivning

Severe liver disease, GOT> 2 x ULN, GPT> 2x ULN, yGT> 2 x ULN, bilirubin> 2 x ULN

Datatyp

integer

Hyperuricemia
Beskrivning

Hyperuricemia

Datatyp

integer

Hyperkalemia
Beskrivning

Hyperkalemia

Datatyp

integer

State after prior PUVA therapy
Beskrivning

State after prior PUVA therapy with cumulative dose> 1000 J / cm²

Datatyp

integer

State after many years of methotrexate therapy
Beskrivning

State after many years of methotrexate therapy

Datatyp

integer

Therapy with Etretinate
Beskrivning

Therapy with Etretinate within 4 weeks prior to initiating therapy with cyclosporine

Datatyp

integer

Concurrent therapy with retinoids
Beskrivning

Concurrent therapy with retinoids

Datatyp

integer

Concurrent therapy with coal tar
Beskrivning

Concurrent therapy with coal tar

Datatyp

integer

Concurrent therapy with simvastatin
Beskrivning

Concurrent therapy with simvastatin

Datatyp

integer

Concurrent therapy with tacrolimus
Beskrivning

Concurrent therapy with tacrolimus

Datatyp

integer

Concomitant use of Hypericum perforatum
Beskrivning

Concomitant use of St. John's wort (Hypericum perforatum)

Datatyp

integer

Concomitant therapy with P-glycoprotein or OATP subtrates
Beskrivning

Concomitant therapy with drugs that are substrates of multidrug efflux transporters P-glycoprotein or Organic Anion Transporting Polypeptides and are joined for the increased plasma concentrations with serious and / or life-threatening events, such as Bosentan, Dabigatran-Etexilate and Aliskiren.

Datatyp

integer

Concomitant vaccination with live vaccines
Beskrivning

Concomitant vaccination with live vaccines

Datatyp

integer

Alcohol disease
Beskrivning

Alcohol disease, contraindication to the use of alcohol (eg. epilepsy)

Datatyp

integer

Erythrodermic or pustular psoriasis
Beskrivning

Erythrodermic or pustular psoriasis

Datatyp

integer

Psoriatic forms that may be caused or exacerbated by drugs
Beskrivning

Psoriatic forms that may be caused or exacerbated by drugs.

Datatyp

integer

Tillbaka till toppen

Similar models

Eligibility Determination Psoriasis MIPSO EudraCT 2014-003022-40

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Patient identification
Patient number
Item
text
Date of consent
Item
Date of consent
date
Date of screening
Item
Date of screening
date
Item Group
Inclusion criteria
Patients with at least moderate psoriasis vulgaris (PASI ≥ 10) plaque-type
Item
boolean
≥18 years (male and female)
Item
boolean
Indications for treatment with adalimumab, ustekinumab or cyclosporine in accordance with the guidelines for psoriasis and the individual prescribing information
Item
boolean
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Additional inclusion criterion for patients who should receive ciclosporin
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item Group
Exclusion criteria
Therapy with systemic immunosuppressants
Item
boolean
Concurrent therapy with systemic immunosuppressants
Item
boolean
Antibiotic therapy over a period of at least 4 weeks or during the study
Item
boolean
Psoriasis patients who currently receive or have received phototherapy
Item
boolean
Patients who can not interrupt the local, topical therapy with calcineurin inhibitors or vitamin D3 analogues in the skin areas
Item
boolean
Clinically significant active infection
Item
boolean
Chronic carriers of the hepatitis B virus
Item
Chronic carriers of the hepatitis B virus (HBsAg positive)
boolean
HIV-positive
Item
HIV-positive patients
boolean
Malignancies current or history
Item
boolean
Immunodeficient patients
Item
Immunodeficient patients (primary disease or as a result of therapy)
boolean
Patients receiving chemotherapy or radiation therapy
Item
boolean
Patients are not stable with uncontrolled chronic diseases
Item
boolean
Patients with other chronic skin diseases
Item
boolean
Patients with psychiatric comorbidity
Item
boolean
Participation in another interventional examination
Item
boolean
Pregnancy or lactation
Item
boolean
Patients who were positive for MRSA
Item
boolean
Patients with psoriasis vulgaris exclusively in the head area
Item
boolean
Item Group
Additional exclusion criteria Adalimumab
Item
integer
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Hypersensitivity
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Moderate to severe heart failure (NYHA class III / IV).
integer
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Moderate to severe heart failure (NYHA class III / IV).
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Demyelinating diseases of the CNS
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concurrent therapy with Anakinra or Abatacept
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concomitant vaccination with live vaccines
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item Group
Additional exclusion criteria Ustekinumab
Item
integer
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Hypersensitivity
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Simultaneous vaccination with live viruses or live bacteria
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item Group
Additional exclusion criteria Ciclosporin
Item
integer
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Hypersensitivity
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Uncontrolled arterial hypertension
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Uncontrolled infectious diseases
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Not healed infection with varicella
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Relevant renal impairment
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Severe liver disease
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
Hyperuricemia
integer
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Hyperuricemia
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
integer
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Hyperkalemia
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
State after prior PUVA therapy
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
State after many years of methotrexate therapy
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Therapy with Etretinate
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concurrent therapy with retinoids
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concurrent therapy with coal tar
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concurrent therapy with simvastatin
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concurrent therapy with tacrolimus
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concomitant use of Hypericum perforatum
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concomitant therapy with P-glycoprotein or OATP subtrates
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Concomitant vaccination with live vaccines
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Item
integer
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Alcohol disease
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Erythrodermic or pustular psoriasis
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Additional inclusion criterion for patients who should receive adalimumab or ustekinumab
Code List
Psoriatic forms that may be caused or exacerbated by drugs
CL Item
yes (1)
CL Item
no (2)
CL Item
NA (3)
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial